Lipid-lowering medications: Fibrates

25,517views

Lipid-lowering medications: Fibrates

Watch later

Watch later

Myocardial infarction
Angina pectoris
Aortic dissection
Aneurysms
Shock
Cor pulmonale
Tricuspid valve disease
Pulmonary valve disease
Mitral valve disease
Aortic valve disease
Hypertrophic cardiomyopathy
Dilated cardiomyopathy
Restrictive cardiomyopathy
Pericarditis and pericardial effusion
Cardiac tamponade
Rheumatic heart disease
Endocarditis
Myocarditis
Premature ventricular contraction
Premature atrial contraction
Atrial fibrillation
Atrial flutter
Atrioventricular nodal reentrant tachycardia (AVNRT)
Wolff-Parkinson-White syndrome
Atrioventricular block
Bundle branch block
Long QT syndrome and Torsade de pointes
Ventricular tachycardia
Brugada syndrome
Ventricular fibrillation
Hypertension
Arterial disease
Vasculitis
Kawasaki disease
Behcet's disease
Deep vein thrombosis
Chronic venous insufficiency
Thrombophlebitis
Nutcracker syndrome
Superior mesenteric artery syndrome
Coronary steal syndrome
Lymphedema
Patent ductus arteriosus
Ventricular septal defect
Atrial septal defect
Coarctation of the aorta
Tetralogy of Fallot
Transposition of the great vessels
Persistent truncus arteriosus
Hypoplastic left heart syndrome
Vascular tumors
Arteriovenous malformation
Cardiac tumors
Angiosarcomas
Class I antiarrhythmics: Sodium channel blockers
Class II antiarrhythmics: Beta blockers
Class III antiarrhythmics: Potassium channel blockers
Class IV antiarrhythmics: Calcium channel blockers and others
ACE inhibitors, ARBs and direct renin inhibitors
Miscellaneous lipid-lowering medications
Lipid-lowering medications: Fibrates
Lipid-lowering medications: Statins
Positive inotropic medications
Sympatholytics: Alpha-2 agonists
Adrenergic antagonists: Alpha blockers
Adrenergic antagonists: Beta blockers
Adrenergic antagonists: Presynaptic
cGMP mediated smooth muscle vasodilators
Calcium channel blockers
IgA nephropathy (NORD)
Rapidly progressive glomerulonephritis
Goodpasture syndrome
Poststreptococcal glomerulonephritis
Lupus nephritis
Minimal change disease
Diabetic nephropathy
Membranoproliferative glomerulonephritis
Membranous nephropathy
Lower urinary tract infection
Acute pyelonephritis
Chronic pyelonephritis
Kidney stones
Renal tubular acidosis
Renal artery stenosis
Renal cortical necrosis
Renal azotemia
Postrenal azotemia
Chronic kidney disease
Hyponatremia
Hypernatremia
Hyperkalemia
Hypokalemia
Hypercalcemia
Hypocalcemia
Hypermagnesemia
Hypomagnesemia
Hyperphosphatemia
Hypophosphatemia
Neurogenic bladder
Urinary incontinence
Renal cell carcinoma
Angiomyolipoma
Nephroblastoma (Wilms tumor)
WAGR syndrome
Non-urothelial bladder cancers
Transitional cell carcinoma
Hydronephrosis
Vesicoureteral reflux
Posterior urethral valves
Bladder exstrophy
Polycystic kidney disease
Horseshoe kidney
Renal agenesis
Medullary sponge kidney
Multicystic dysplastic kidney
Medullary cystic kidney disease
Potter sequence
Parasympathetic nervous system
Central nervous system histology
Somatosensory pathways
Peripheral nervous system histology
Rheumatoid arthritis
Reactive arthritis
Psoriatic arthritis
Gout
Ankylosing spondylitis
Systemic lupus erythematosus
Scleroderma
Raynaud phenomenon
Limited systemic sclerosis (CREST syndrome)
Sjogren syndrome
Fibromyalgia
Polymyalgia rheumatica
Amyloidosis
Dermatomyositis
Polymyositis
Inclusion body myopathy
Osteoarthritis
Slipped capital femoral epiphysis
Paget disease of bone
Osteomalacia and rickets
Osteoporosis
Osgood-Schlatter disease (traction apophysitis)
Legg-Calve-Perthes disease
Septic arthritis
Osteomyelitis
Lordosis, kyphosis, and scoliosis
Rotator cuff tear
Meniscus tear
Compartment syndrome
Bone tumors
Developmental dysplasia of the hip
Cleidocranial dysplasia
Achondroplasia

Transcript

Watch video only

Content Reviewers

Fibrates are a group of lipid-lowering medications, along with statins and niacin.

These medications are very effective at lowering triglyceride levels in the blood, but are less effective at controlling cholesterol.

Now, triglycerides make up most of your body fat, and they consist of a glycerol and 3 fatty acids.

So when we eat a box of chili fries, the fatty acids and cholesterol are absorbed into the cells in the small intestine.

The fatty acids are then converted into triglycerides.

However, triglycerides and cholesterol are not water soluble, so they can’t travel freely in the blood. To fix this, our body makes “shipping boxes” called lipoproteins.

These containers consist of a shell made of phospholipids and protein tags that act as instructions for their destination.

So after absorption, the small intestinal cells package the triglycerides and cholesterol into the largest, but least dense lipoproteins, called chylomicrons.

These are released into the lymphatic system and then enter the bloodstream via the subclavian vein. Then, they travel through the blood to reach the liver and other tissues in the body.

Now in the blood vessels near these tissues, we have an enzyme called lipoprotein lipase, which can break down triglycerides into fatty acids.

Cells in the nearby tissue can then use these fatty acids to generate ATP.

Adipose tissue can synthesize a lot of lipoprotein lipases, which means they have access to a lot of fatty acids.

Now, instead of using the fatty acids for energy, they pick them up, convert them back into triglycerides, and store them for later use.

Okay, so we can also synthesize fatty acids from glucose in the liver which are then converted into triglycerides.

These triglycerides and some cholesterol are packed into the next kind of lipoproteins called very-low-density lipoproteins or VLDL, which are smaller and more dense than chylomicrons.

This package is sent into the bloodstream to carry the energy-rich triglycerides to the rest of the body.

Now, lipoprotein lipases in the blood vessels will once again convert the triglycerides in the VLDLs into fatty acids, which can enter the cells; and the leftover VLDLs are called VLDL remnants.

This and the remaining cholesterol are converted into a new kind of lipoprotein, called a low-density lipoprotein, or LDL, which are even smaller and more dense than VLDL.

These will travel around the bloodstream and deliver cholesterol to cells in the rest of the body.

The final lipoprotein is the HDL, or high-density lipoprotein, which are smaller and denser than LDLs.

These are like the boxes you get when you try to return an item you bought online.

In this case, the liver produces HDL and releases them into the blood, where they pick up excess cholesterol from the peripheral tissues and brings them back to the liver.

So in essence, it’s the opposite of LDL, which carries cholesterol from the liver to the peripheral tissues.

Now, triglycerides are atherogenic which means they can cause atherosclerosis, increasing the risk of cardiovascular complications like strokes and myocardial infarctions.

Extremely high triglyceride levels can also lead to acute pancreatitis.

Okay, so if we want to lower triglyceride levels we can use a class of medications called fibrates.

Sources

  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
  4. "PPAR Agonists and Metabolic Syndrome: An Established Role?" International Journal of Molecular Sciences (2018)
  5. "Fibrates for primary prevention of cardiovascular disease events" Cochrane Database of Systematic Reviews (2016)
  6. "PPAR-Induced Fatty Acid Oxidation in T Cells Increases the Number of Tumor-Reactive CD8+ T Cells and Facilitates Anti–PD-1 Therapy" Cancer Immunology Research (2018)
  7. "Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study" BMJ (2019)